Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Reata Pharmaceuticals (NASDAQ: RETA) reported Q2 EPS of ($0.05), versus ($0.11) reported last year. Revenue for the quarter came in at $12.4 million, versus $12.4 million reported last year.
For earnings history and earnings-related data on Reata Pharmaceuticals (RETA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exelon Corp. (EXC) Tops Q3 EPS by 12c
- Vonage (VG) Tops Q3 EPS by 4c
- Mondelez Int'l (MDLZ) Tops Q3 EPS by 9c, Offers Outlook
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!